CIS-DICHLORODIAMMINEPLATINUM(II) IN ADVANCED BLADDER CANCER

Abstract

Cis-Dichlorodiammineplatinum(II) (DDP) was given at a dose of 1.25 or 1.6 mg/kg to 24 patients with advanced measurable urinary tract cancer. Eight patients (35%) achieved a partial remission and 4 additional patients had a minor response. There were 14 patients with epidermoid (transitional cell) bladder cancer who had no prior chemotherapy, and all 8 partial responders were in this group. DDP appears to be 1 of the more active antineoplastic agents in bladder cancer.